Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA known ✓ | P35790 | 5/20 | 0.33 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5442083 | 0.98 | CDK5 (0.31) | CHKABCHEACHECDK5CDK5R1 | |
| SCHEMBL5444936 | 0.94 | CDK5 (0.30) | CDK5CDK5R1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5450101 | 0.89 | ACHE (0.34) | ACHE | |
| Bromide SCHEMBL5446449 | 0.88 | BCHE (0.32) | CHKABCHEACHE | |
| Hydrochloric Acid SCHEMBL5448174 | 0.86 | — | — | |
| SCHEMBL5441442 | 0.83 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL5451632 | 0.78 | — | — | |
| Bromide SCHEMBL5442832 | 0.71 | — | — | |
| Bromide SCHEMBL5453344 | 0.70 | — | — | |
| Bromide SCHEMBL4392858 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| CN-1835957-A | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2006-09-20 | — | — | CN | claimed |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| CN-1835957-A | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2006-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | IDH1, IDH3B, MIF | CHKA 3757/4885ACHE 3129/4885BCHE 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.